Related Experiment Video
Updated: Nov 3, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Treatment of Rare Mutations in Patients with Lung Cancer
Tarek Taha1, Rasha Khoury2, Ronen Brenner3
1Oncology Institute, Technion Faculty of Medicine, Rambam Health Care Campus, 8 HaAliyah HaShniyah Street, 3525408 Haifa, Israel.
Abstract:
Lung cancer is a worldwide prevalent malignancy. This disease has a low survival rate due to diagnosis at a late stage challenged by the involvement of metastatic sites. Non-small-cell lung cancer (NSCLC) is presented in 85% of cases. The last decade has experienced substantial advancements in scientific research, leading to a novel targeted therapeutic approach. The newly developed pharmaceutical agents are aimed towards specific mutations, detected in individual patients inflicted by lung cancer. These drugs have longer and improved response rates compared to traditional chemotherapy. Recent studies were able to identify rare mutations found in pulmonary tumors. Among the gene alterations detected were mesenchymal epithelial transition factor (MET), human epidermal growth factor 2 (HER2), B-type Raf kinase (BRAF), c-ROS proto-oncogene (ROS1), rearranged during transfection (RET) and neurotrophic tyrosine kinase (NTRK). Ongoing clinical trials are gaining insight onto possible first and second lines of medical treatment options intended to enable progression-free survival to lung cancer patients.
Insights
Novel targeted therapies show promise for lung cancer patients by targeting specific gene mutations like MET, HER2, BRAF, ROS1, RET, and NTRK, improving outcomes beyond traditional chemotherapy.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer mortality globally, often diagnosed at advanced stages with metastasis.
- Non-small-cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, highlighting the need for effective treatments.
- Low survival rates underscore the urgency for innovative therapeutic strategies.
Purpose of the Study:
- To review recent advancements in targeted therapies for lung cancer.
- To highlight the identification of rare gene mutations as therapeutic targets.
- To discuss the potential of novel agents in improving patient survival and progression-free survival.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Identification and analysis of specific gene mutations in pulmonary tumors.
- Evaluation of targeted pharmaceutical agents against identified mutations.
Main Results:
- Novel targeted therapies demonstrate improved response rates compared to traditional chemotherapy.
- Specific gene alterations including MET, HER2, BRAF, ROS1, RET, and NTRK have been identified in lung tumors.
- Ongoing clinical trials are exploring these targeted agents for first and second-line treatments.
Conclusions:
- Targeted therapies represent a significant advancement in lung cancer treatment.
- Precision medicine approaches focusing on individual mutations offer improved outcomes for NSCLC patients.
- Further research and clinical trials are crucial for optimizing treatment strategies and enhancing progression-free survival.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers